{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:50:09Z","timestamp":1753890609390,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Several studies have summarized the clinical performance of direct oral anticoagulants (DOACs) in atrial fibrillation (AF) patients with mitral stenosis or aortic stenosis. The significance of this review was to provide clinicians the latest update of the clinical application of DOACs in managing this specific population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Literatures from the PubMed database up to July 2022 were screened for inclusion. Studies on the effect of DOACs in patients suffering from AF with mitral or aortic stenosis were assessed for further selection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Results from four studies were gathered: the RISE MS trial, the DAVID-MS study, and two observational studies. In the Korean observational study with a 27-month follow-up duration and a sample population consisted of patients with mitral stenosis and AF, the thromboembolic events happened at a rate of 2.22%\/ year in the DOAC group and 4.19%\/year in the warfarin group (adjusted hazard ratio: 0.28; 95% CI: 0.18\u20130.45). Intracranial hemorrhage occurred at rates of 0.49% and 0.93% in the DOAC and the warfarin groups, respectively (adjusted hazard ratio: 0.53; 95% CI: 0.22\u20131.26). In the Danish observational study, which had a sample pool with AF patients with aortic stenosis, reported that the adjusted hazard ratios for thromboembolism and major bleeding were 1.62 (95% CI, 1.08\u20132.45) and 0.73 (95% CI, 0.59\u20130.91) for DOACs compared with warfarin during 3 years of follow-up. In the RISE-MS trial involving AF patients with mitral stenosis, there were no differences in ischemic stroke, systemic embolic events, or major bleeding between the rivaroxaban vs. warfarin groups during a 1-year follow-up as well as equal rate of increased thrombogenicity in the left atrial appendage at 6 months. The rate of silent cerebral ischemia at 12 months was higher in the warfarin group (17.6%) than that in the rivaroxaban group (13.3%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Current published studies supported DOACs' effectiveness in preventing thromboembolism in patients of AF with mitral or aortic stenosis. Further clinical trials could confirm these findings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.1070806","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T05:43:15Z","timestamp":1668577395000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of direct oral anticoagulants in patients with atrial fibrillation with mitral or aortic stenosis: A review"],"prefix":"10.3389","volume":"9","author":[{"given":"Guigao","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shucheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeyu","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4330\/wjc.v11.i2.71","article-title":"Heart valve disease in elderly","volume":"11","author":"Rostagno","year":"2019","journal-title":"World J Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/heartjnl-2017-311425","article-title":"Management of atrial fibrillation in patients with rheumatic mitral stenosis","volume":"104","author":"Iung","year":"2018","journal-title":"Heart."},{"key":"B3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1476-7120-10-38","article-title":"Atrial fibrillation in aortic stenosis\u2013echocardiographic assessment and prognostic importance","volume":"10","author":"Burup K","year":"2012","journal-title":"Cardiovasc Ultrasound."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.4022\/jafib.2143","article-title":"Prevalence and factors associated with atrial fibrillation among patients with rheumatic heart disease","volume":"12","author":"Dhungana S","year":"2019","journal-title":"J Atr Fibrillation."},{"key":"B5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijchv.2014.06.006","article-title":"Atrial fibrillation in severe aortic valve stenosis \u2014 association with left ventricular left atrial remodeling","volume":"4","author":"Dahl J","year":"2014","journal-title":"IJC Heart & Vessels."},{"key":"B6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/europace\/euab065","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"R665","DOI":"10.1161\/CIR.0000000000000665","article-title":"AHA\/ACC\/HRS focused update of the (2014). AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons","volume":"140","author":"January C","year":"2019","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1056\/NEJMc2114895","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S2352-3026(17)30014-5","article-title":"Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: THE open-label, randomised, non-inferiority surprise phase 3B trial","author":"Beyer-Westendorf","year":"2017","journal-title":"Lancet Haematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jth.15126","article-title":"New anticoagulants: moving beyond the direct oral anticoagulants","volume":"19","author":"Fredenburgh","year":"2020","journal-title":"J Thromb Haemost."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban vs. warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1161\/CIRCULATIONAHA.121.058159","article-title":"A patient-level meta-analysis: the end of the era of direct oral anticoagulant developmental trials in patients with atrial fibrillation?","volume":"145","author":"Goto","year":"2022","journal-title":"Circulation."},{"key":"B16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban vs. warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban vs. warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel M","year":"2011","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran vs. warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly S","year":"2009","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"757188","DOI":"10.3389\/fcvm.2021.757188","article-title":"Reappraisal of non-vitamin k antagonist oral anticoagulants in atrial fibrillation patients: a systematic review and meta-analysis","volume":"8","author":"Liu","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"766377","DOI":"10.3389\/fcvm.2021.766377","article-title":"Effectiveness and safety of DOACs vs. VKAs in AF patients with cancer: evidence from randomized clinical trials and observational studies","volume":"8","author":"Liu","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10557-021-07144-8","article-title":"Effect of rivaroxaban or apixaban in atrial fibrillation patients with stage 4\u20135 chronic kidney disease or on dialysis","volume":"35","author":"Chen","year":"2021","journal-title":"Cardiovasc Drugs Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10557-020-06962-6","article-title":"Non-vitamin K antagonist oral anticoagulants vs. warfarin in patients with atrial fibrillation and peripheral artery disease: a systematic review and meta-analysis","volume":"34","author":"Liao","year":"2020","journal-title":"Cardiovasc Drugs Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10557-020-06961-7","article-title":"Non-vitamin K antagonist oral anticoagulants in secondary stroke prevention in atrial fibrillation patients: an updated analysis by adding observational studies","volume":"34","author":"Liu","year":"2020","journal-title":"Cardiovasc Drugs Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40256-018-0299-7","article-title":"Efficacy and safety of the use of non-vitamin k antagonist oral anticoagulants in patients with ischemic heart disease: a meta-analysis of phase III randomized trials","volume":"19","author":"Fu","year":"2019","journal-title":"Am J Cardiovasc Drugs."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008773","article-title":"2018 safety and efficacy of novel oral anticoagulants vs. warfarin in Medicare beneficiaries with Atrial Fibrillation and valvular heart disease","author":"Briasoulis","year":"","journal-title":"Am Heart J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"910","DOI":"10.7326\/M20-6194","article-title":"Effectiveness and safety of direct oral anticoagulants vs. warfarin in patients with Valvular Atrial Fibrillation","volume":"174","author":"Dawwas","year":"2021","journal-title":"Ann Intern Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/03007995.2021.1885365","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease","volume":"37","author":"Li","year":"2021","journal-title":"Curr Med Res Opin."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.3390\/jcm8101624","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease","volume":"8","author":"Moon","year":"2019","journal-title":"J Clin Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ijcard.2022.03.037","article-title":"RIvaroxaban in mitral stenosis (RISE MS): A pilot randomized clinical trial","volume":"356","author":"Sadeghipour","year":"2022","journal-title":"Int J Cardiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e022628","DOI":"10.1161\/JAHA.121.022628","article-title":"Effectiveness and safety of NOAC vs. warfarin in patients with atrial fibrillation and aortic stenosis","volume":"10","author":"Melgaard","year":"2021","journal-title":"Am Heart J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e38194","DOI":"10.1136\/bmjopen-2020-038194","article-title":"Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study","volume":"10","author":"Zhou","year":"2020","journal-title":"BMJ Open."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jacc.2018.12.048","article-title":"DOACs in patients with mitral stenosis and atrial fibrillation","volume":"73","author":"Giugliano","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacc.2018.12.047","article-title":"Outcomes of direct oral anticoagulants in patients with mitral stenosis","volume":"73","author":"Kim J","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"715878","DOI":"10.3389\/fcvm.2021.715878","article-title":"Use of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the international guidelines","volume":"8","author":"Pastori","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/PGPM.S187350","article-title":"VKORC1 variants as significant predictors of warfarin dose in Emiratis","volume":"12","author":"Al-Mahayri","year":"2019","journal-title":"Pharmacogenomics Res Pers Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/jcpt.13334","article-title":"A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional","volume":"46","author":"Sridharan","year":"2020","journal-title":"J Clin Pharm Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.ihj.2018.02.005","article-title":"Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit","volume":"3","author":"Biswas","year":"2018","journal-title":"Indian Heart J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"FI1","DOI":"10.1093\/ehjcvp\/pvaa011","article-title":"All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease","volume":"7","author":"Strange","year":"2020","journal-title":"Eur Heart J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease\u2013associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1070806\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T05:43:17Z","timestamp":1668577397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1070806\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":40,"alternative-id":["10.3389\/fcvm.2022.1070806"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.1070806","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"article-number":"1070806"}}